ProMetic Life Sciences Inc. (TSE:PLI) insider Bruce Pritchard bought 48,400 shares of ProMetic Life Sciences stock in a transaction dated Tuesday, August 22nd. The shares were bought at an average cost of C$1.30 per share, for a total transaction of C$62,920.00. This trade was viewed 273 times. Read More. •ProMetic Life Sciences Inc. (TSE:PLI) insider Patrick Sartore bought 9,250 shares of ProMetic Life Sciences stock in a transaction dated Friday, August 18th. The shares were bought at an average cost of C$1.21 per share, for a total transaction of C$11,192.50. This trade was viewed 205 times. Read More. •ProMetic Life Sciences Inc. (TSE:PLI) Director Simon Geoffrey Best bought 10,000 shares of ProMetic Life Sciences stock in a transaction dated Tuesday, August 22nd. The shares were bought at an average cost of C$1.29 per share, for a total transaction of C$12,900.00. This trade was viewed 165 times. Read More.
Prometic Receives Rare Pediatric Disease Designation From U.S. FDA for its Plasminogen Replacement Therapy
This company heavily invest on products so near future , eps is not good ; won't move much However has the potential Pure risk
Best Penny, OTC Stocks and Dividend Stocks to Buy - J Charles Assets
We search for the smart new growing companies to invest in with stock deals to watch in pharmacuetical and digital verticals.
why no post
Searching for the perfect play at the perfect time? Look no further than SmallCapCanada, simply the best reports featuring the biggest opportunities on the TSX, TSX-V, and CSE. www.smallcapcanada.com
SMALL CAP CANADA
I see SANOFI is looking for a partner in the same research PLI just discussed in their press release. Coincidence or intentional?
Shorts you going to get burned
Just finished listening to conference call Mar31 Management seems confident pending final approvals, The answered straight forward questions,did not attempt to hide facts. I think 2017 and 2018 will be good years. I'm buying in more stock at this price 2.25
always over promising and under delivering for over a decade. This is a negative predictor of the company's many many rosy predictions. I want to believe in their Hopium but I'm out.
Il se passe quoi ce matin
I had bought it near 52w high. now when i look at it, I wish I sold. I even have the US equity too from 52w high :'(. what should I do now? sell or hold on. um 55% down!
somethingis still not right this stock is still crashing and crashing andcraashing iity keep on crashing andcrashing today this couldcrashbelow $1.20 in the coming days it keeps on crashing so something is not right
Is there anything promising with all of the protein technology, treatments for fibrosis, autoimmune disease/cancer or anything else with this Company? The plasminogen drug should not be a major driver for earnings IMO. Why after 25 years in existence is the stock price at 1.17 per share? Can anyone with scientific or medical background comment intelligently on if this company has any real prospects?
Why is there no insider buying/selling history or analyst opinion listed? There are very interesting research targets but I see no conferences/presentations/events upcoming. Why are the salaries of the management about $2 million per year with so little real results and no transparency by the Company?